Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2878 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 07 Nov 2026, 03:15 UTC
2878
Studies in scope
industry-sponsored, all four open statuses
1386
Recruiting now
open to new participants
546
Lead sponsors
across recruiting studies
Top sites
London 139 Manchester 77 Cambridge 66 Glasgow 35 Edinburgh 34
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca139 Merck Sharp & Dohme LLC97 Hoffmann-La Roche82 Novartis Pharmaceuticals72 Janssen Research & Development, LLC70 Clear sponsor filter
Site city
London139 Manchester77 Cambridge66 Glasgow35 Edinburgh34
All 135 cities
Target enrolment
to

Trials with a site in London

139 of 2878 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
AstraZeneca
Phase 3
750
Cambridge, London
2026-09-24
Recruiting
AstraZeneca
Phase 3
1,330
Cambridge, Glasgow, London, Manchester, Plymouth
2026-09-15
Recruiting
AstraZeneca
Phase 3
2,800
Aberdeen, Bristol, Cardiff, Dundee, Glasgow, London, Swansea
2026-09-01
Recruiting
AstraZeneca
Phase 3
1,072
Cambridge, Leeds, London, Newcastle upon Tyne, Sheffield
2026-08-31
Recruiting
AstraZeneca
Phase 3
600
Coventry, Knutsford, London, Orpington, Poole, Shipley
2026-08-12
Recruiting
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
NCT07444567Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
DrugsFasenra·Benralizumab
AstraZeneca
Phase 3
230
London
2026-07-24
Recruiting
AstraZeneca
Phase 3
750
Edinburgh, London, Manchester
2026-06-26
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Bristol, Cottingham, Edinburgh, Exeter, Liverpool, London
2026-06-11
Active, closed
AstraZeneca
Phase 2
326
London
2026-06-11
Recruiting
AstraZeneca
Phase 2
80
Colchester, Derby, Edgbaston, Exeter, Leeds, London, Southampton
2026-06-04
Recruiting
AstraZeneca
Phase 1/2
152
Belfast, Fulham, Guildford, London, Newcastle upon Tyne, Oxford
2026-06-03
Recruiting
AstraZeneca
Phase 2
24
Cambridge, London, Manchester
2026-05-06
Recruiting
AstraZeneca
Phase 3
420
Edinburgh, Hampshire, Leeds, London, Manchester, Nottingham, Oxford, Sutton
2026-05-05
Recruiting
AstraZeneca
Phase 3
670
London, Middlesbrough, Southampton, Truro
2026-05-04
Recruiting
AstraZeneca
Phase 2
43
London, Manchester
2026-03-28
Recruiting
AstraZeneca
Phase 1/2
180
Cambridge, London, Sutton
2026-03-17
Recruiting
AstraZeneca
Phase 3
508
Birmingham, Bristol, Glasgow, Scotland, London
2026-02-23
Recruiting
AstraZeneca
Phase 2
124
Brighton, Guildford, Liverpool, London
2026-02-10
Recruiting
AstraZeneca
Phase 3
2,130
Cambridge, Dundee, Leeds, London, Manchester, Oxford
2026-02-03
Recruiting
AstraZeneca
Phase 1/2
85
Edinburgh, London, Manchester, Newcastle
2026-01-09
Recruiting
A Study of AZD0120 in Autoimmune Diseases
NCT07295847Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
DrugAZD0120
AstraZeneca
Phase 1/2
27
Edinburgh, London
2026-01-09
Recruiting
AstraZeneca
Phase 3
1,100
Barrow in Furness, Birmingham, Cambridge, Canterbury, Cardiff, Edinburgh, Greater London, London
2025-12-29
Recruiting
AstraZeneca
Phase 1
24
Cambridge, London
2025-12-09
Active, closed
AstraZeneca
Phase 2
222
Dundee, Liverpool, London
2025-12-05
Recruiting
AstraZeneca
Phase 3
1,100
Birmingham, Glasgow, Greater London, Leeds, London, Manchester
2025-12-04
Recruiting
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
NCT07201558Rheumatoid Arthritis, Systemic Lupus Erythematosus
DrugSurovatamig
AstraZeneca
Phase 1
48
London
2025-12-02
Recruiting
AstraZeneca
Phase 4
56
Harefield, London, Manchester
2025-11-24
Recruiting
AstraZeneca
Phase 3
420
Glasgow, Scotland, London, Manchester, Newcastle upon Tyne, Nottingham
2025-11-11
Recruiting
AstraZeneca
Phase 1
40
London
2025-11-10
Recruiting
AstraZeneca
Phase 1
72
London, Manchester
2025-11-03
Recruiting
AstraZeneca
Phase 3
400
Huddersfield, London, Maidstone, Norwich, Stoke-on-Trent
2025-10-31
Recruiting
AstraZeneca
Phase 1/2
283
Cambridge, London, Plymouth, Sutton
2025-10-01
Recruiting
AstraZeneca
Phase 1/2
164
London, Newcastle upon Tyne
2025-09-24
Active, closed
AstraZeneca
Phase 3
212
Cambridge, Cardiff, Dundee, London
2025-08-07
Recruiting
AstraZeneca
Phase 3
800
Bebington, Canterbury, Derby, London, Manchester, Northwood, Truro
2025-08-01
Recruiting
AstraZeneca
Phase 2
100
Bristol, Dundee, Headington, London, Norwich
2025-07-17
Recruiting
AstraZeneca
Phase 2
987
Bradford, Cottingham, Glasgow, Harrow, London, Newcastle upon Tyne, Thetford, Wythenshawe
2025-06-27
Active, closed
AstraZeneca
Phase 3
3,103
Chesterfield, Chippenham, Corby, Coventry, Harrow, Hull, London, Northwood
2025-05-28
Recruiting
AstraZeneca
Phase 3
1,220
Cambridge, Leeds, London, Manchester
2025-05-06
Recruiting
AstraZeneca
Phase 1
72
Glasgow, London, Southampton
2025-05-01
Active, closed
Study for AZD4360 in Participants With Advanced Solid Tumours
NCT06921928Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
AstraZeneca
Phase 1/2
31
Glasgow, London
2025-04-29
Active, closed
AstraZeneca
Observational
2,000
London
2025-04-17
Recruiting
AstraZeneca
Phase 3
600
Bath, Cambridge, Leeds, London, Manchester, Northwood, Taunton
2025-03-27
Recruiting
AstraZeneca
Phase 3
11,300
Aberdeen, Chesterfield, Dundee, Gatley, Glasgow, London, Norwich, Penzance
2025-03-14
Active, closed
AstraZeneca
Phase 2
82
Cambridge, London, Manchester, Metropolitan Borough of Wirral
2025-03-12
Active, closed
AstraZeneca
Phase 2
63
Birmingham, Leicester, Liverpool, London, Manchester
2025-03-05
Recruiting
AstraZeneca
Phase 3
5,000
Bradford, Bristol, Canterbury, Cardiff, Dundee, Glasgow, Hounslow, London
2025-03-03
Recruiting
AstraZeneca
Phase 3
840
Cambridge, Coventry, Dundee, London, Manchester, Sutton
2025-03-01
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin
AstraZeneca
Phase 1/2
408
Derriford, London, Oxford, Southampton
2025-01-30
Active, closed
AstraZeneca
Phase 2
24
Birmingham, Cambridge, London
2024-12-11
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
DrugSurovatamig
AstraZeneca
Phase 2
270
London, Manchester, Norwich, Nottingham, Plymouth
2024-11-27
Recruiting
AstraZeneca
Phase 3
1,160
Aberdeen, Cambridge, Edinburgh, Exeter, Greater London, London, Manchester, Newcastle upon Tyne
2024-11-27
Recruiting
AstraZeneca
Phase 3
1,160
Aberdeen, Cambridge, Edinburgh, Exeter, Greater London, London, Manchester, Newcastle upon Tyne
2024-11-18
Active, closed
AstraZeneca
Phase 3
768
Birmingham, Cambridge, Glasgow, Leicester, London, Manchester
2024-10-04
Active, closed
AstraZeneca
Phase 3
310
Belfast, Liverpool, London, Southampton
2024-09-30
Recruiting
AstraZeneca
Observational
24,000
Edinburgh, London
2024-09-30
Recruiting
AstraZeneca
Phase 3
620
Birmingham, Dundee, Glasgow, Greater London, Leeds, London
2024-08-12
Recruiting
AstraZeneca
Phase 3
1,018
London, Newcastle upon Tyne, Norwich, Nottingham, Plymouth, Southampton
2024-08-07
Recruiting
AstraZeneca
Phase 3
788
Cambridge, Guildford, London, Manchester, Oxford, Swansea, Taunton, Truro
2024-08-01
Active, closed
AstraZeneca
Phase 3
339
Cambridge, Leeds, London, Newcastle upon Tyne
2024-06-29
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
Birmingham, Glasgow, London
2024-06-25
Recruiting
AstraZeneca
Phase 3
240
Edinburgh, London, Wolverhampton
2024-06-20
Recruiting
AstraZeneca
Phase 3
675
Cheltenham, Inverness, London, Norwich, Preston, Truro
2024-04-11
Recruiting
AstraZeneca
Phase 3
100
Birmingham, Bristol, Liverpool, London, Manchester, Southampton
2024-03-14
Active, closed
AstraZeneca
Phase 3
594
Cambridge, London, Manchester, Oxford, Taunton
2024-03-04
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
London, Manchester, Surrey
2023-12-29
Recruiting
AstraZeneca
Phase 3
1,145
Aberdeen, Cambridge, Hampshire, Leeds, London, Manchester, Metropolitan Borough of Wirral, Northwood
2023-12-14
Recruiting
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
NCT06219941Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
DrugsL-leucovorin·Nanoliposomal Irinotecan·Onivyde·Sonesitatug Vedotin
AstraZeneca
Phase 2
226
Glasgow, Leeds, London, Oxford
2023-12-13
Active, closed
AstraZeneca
Phase 2
108
Birmingham, Gloucester, London, Norwich, Nottingham, Plymouth
2023-12-13
Active, closed
AstraZeneca
Phase 1/2
55
Cambridge, London, Manchester
2023-12-05
Active, closed
AstraZeneca
Phase 3
760
Cambridge, Edgbaston, Glasgow, Scotland, London, Manchester, Sutton
2023-12-04
Recruiting
AstraZeneca
Phase 3
625
Cardiff, Chelsea, Leicester, Liverpool, London, Oxford, Surrey, Sutton
2023-11-23
Active, closed
AstraZeneca
Phase 3
1,898
Aberdeen, Birmingham, Cambridge, Glasgow, Guildford, London, Manchester, Newcastle upon Tyne
2023-11-21
Active, closed
AstraZeneca
Phase 3
1,902
Birmingham, Cardiff, Lancaster, London, Northampton, Oxford, Taunton
2023-11-14
Active, closed
AstraZeneca
Phase 3
863
Cambridge, Leeds, Leicester, London, Manchester, Newcastle upon Tyne, Portsmouth, Taunton
2023-11-09
Active, closed
AstraZeneca
Phase 3
314
Cannock, Leeds, London, Sheffield
2023-11-08
Active, closed
AstraZeneca
Phase 3
1,835
Cardiff, Dundee, Glasgow, London, York
2023-11-07
Active, closed
AstraZeneca
Phase 3
895
Birmingham, Blackpool, Bury St Edmunds, Colchester, London, Truro
2023-10-24
Recruiting
AstraZeneca
Phase 3
231
Birmingham, Bradford, Bristol, Glasgow, Leicester, London, Nottingham, Stoke-on-Trent
2023-08-24
Recruiting
AstraZeneca
Observational
52,121
London
2023-08-21
Recruiting
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
NCT06005493Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
DrugRilvegostomig
AstraZeneca
Phase 1/2
392
Dundee, London, Metropolitan Borough of Wirral, Oxford
2023-07-11
Recruiting
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
DrugsPalacaparib·Torvutatug samrotecan·Saruparib·Paraplatin
AstraZeneca
Phase 1/2
622
Cambridge, Glasgow, Scotland, London, Sutton
2023-06-05
Active, closed
AstraZeneca
Phase 2
294
Cambridge, London, Manchester
2023-04-24
Active, closed
AstraZeneca
Phase 3
94
London, Manchester
2023-04-05
Active, closed
AstraZeneca
Phase 2
188
London, Nottingham
2023-03-06
Recruiting
AstraZeneca
Phase 2
163
Edinburgh, Leeds, London, Oxford
2023-01-16
Active, closed
AstraZeneca
Phase 3
1,350
Aberdeen, Cambridge, Cardiff, Cheltenham, Edinburgh, London, Manchester, Middlesbrough
2022-12-29
Recruiting
AstraZeneca
Phase 3
3,527
Bristol, Dundee, Glasgow, Hampshire, Huddersfield, Leeds, Leicester, London
2022-12-13
Active, closed
AstraZeneca
Phase 3
1,174
Cambridge, Cardiff, Edinburgh, Greater London, London, Londonderry, Manchester, Newcastle upon Tyne
2022-11-28
Active, closed
AstraZeneca
Phase 3
368
London
2022-11-10
Recruiting
AstraZeneca
Phase 2
454
Cambridge, Dundee, London, Manchester
2022-09-06
Active, closed
AstraZeneca
Phase 3
341
London, Manchester, Wolverhampton
2022-08-03
Recruiting
AstraZeneca
Phase 1/2
695
Glasgow, Scotland, London, Newcastle upon Tyne
2022-06-24
Active, closed
PASS of Paediatric Patients Initiating Selumetinib
NCT05388370Neurofibromatosis Type 1
AstraZeneca
Observational
124
London, Manchester, Newcastle upon Tyne
2022-05-23
Active, closed
AstraZeneca
Phase 3
644
Bristol, Cardiff, Edinburgh, London, Northampton, Nottingham, Warwick
2022-05-16
By invitation
AstraZeneca
Phase 3
214
London, Sheffield
2022-04-19
Active, closed
AstraZeneca
Phase 3
1,035
Edinburgh, Glasgow, Guildford, Hackensack, London, Manchester, Southampton, Sutton
2022-03-25
Active, closed
AstraZeneca
Phase 3
390
Birmingham, Blackpool, London, Nottingham, Wythenshawe
2022-02-21
Active, closed
AstraZeneca
Phase 3
791
Birmingham, Brighton, Cardiff, Cheltenham, Edinburgh, High Heaton/Newcastle Upon Tyn, Leeds, London
2022-02-18
Active, closed
AstraZeneca
Phase 3
1,051
Belfast, Bristol, Dundee, Edinburgh, London, Middlesbrough, Poole, Torquay
2022-02-07
Active, closed
AstraZeneca
Phase 3
145
London, Manchester
2021-11-19
Active, closed
AstraZeneca
Phase 3
148
Leicester, London
2021-10-28
Recruiting
AstraZeneca
Phase 1/2
460
Cambridge, Cardiff, London
2021-10-18
Active, closed
AstraZeneca
Phase 3
732
Blackpool, Bristol, Cardiff, Colchester, Edinburgh, London, Manchester, Nottingham
2021-10-18
Active, closed
AstraZeneca
Phase 3
712
London
2021-08-05
Active, closed
AstraZeneca
Phase 3
315
Blackpool, Cambridge, London, Manchester, Newport, Nottingham, Portsmouth, Reading
2021-06-30
Active, closed
AstraZeneca
Phase 3
367
Doncaster, Leeds, London
2021-06-08
Active, closed
AstraZeneca
Phase 3
893
Guildford, London, Londonderry, Taunton, York
2021-05-10
Active, closed
AstraZeneca
Phase 3
1,157
Edinburgh, Guildford, London, Manchester, Swansea, Taunton
2021-04-26
Active, closed
AstraZeneca
Phase 3
957
Cambridge, Dundee, Glasgow, Leicester, London, Manchester, Oxford, Surrey
2020-11-17
Active, closed
AstraZeneca
Phase 3
370
London, Manchester, Newcastle upon Tyne, Sutton
2020-10-02
Active, closed
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
NCT04482309Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 2
477
London, Manchester, Sutton
2020-08-18
Active, closed
AstraZeneca
Phase 3
185
Birmingham, Edinburgh, Glasgow, Hull, London, Manchester, Taunton
2020-08-04
Active, closed
AstraZeneca
Phase 3
866
Cambridge, Cardiff, Edinburgh, Guildford, Leeds, London, Manchester, Northwood
2020-07-24
Active, closed
AstraZeneca
Phase 3
134
London
2020-07-20
Active, closed
AstraZeneca
Phase 2
452
Cambridge, Dundee, London, Manchester, Sutton
2020-06-03
Active, closed
AstraZeneca
Phase 3
818
Aberdeen, Bournemouth, Bristol, Cardiff, Cheltenham, London, Manchester, Sutton
2020-04-16
Active, closed
AstraZeneca
Phase 3
140
Cambridge, Leicester, London, Portsmouth
2019-10-29
Active, closed
AstraZeneca
Phase 4
75
Cambridge, Headington, Leicester, Liverpool, London, Wythenshawe
2019-10-08
Active, closed
AstraZeneca
Phase 3
923
Edinburgh, London, Sheffield, Surrey, York
2019-06-25
Active, closed
AstraZeneca
Phase 3
810
Bristol, Cambridge, London, Manchester, Oxford, Romford, Sheffield
2019-04-16
Active, closed
Durvalumab and Tremelimumab for Pediatric Malignancies
NCT03837899Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
DrugDurvalumab
AstraZeneca
Phase 1/2
50
Leeds, London, Sutton
2019-03-07
Active, closed
AstraZeneca
Phase 3
724
Birmingham, Leeds, London, Manchester
2019-03-06
Active, closed
AstraZeneca
Phase 1/2
243
Cambridge, London, Manchester, Oxford
2018-12-21
Active, closed
AstraZeneca
Phase 3
1,063
Edinburgh, London, Metropolitan Borough of Wirral, Nottingham, Sheffield
2018-11-16
Active, closed
AstraZeneca
Phase 1
396
Cambridge, Leeds, London, Manchester, Sutton
2018-10-11
Active, closed
AstraZeneca
Phase 3
1,018
Birmingham, Glasgow, Guildford, London, Sheffield, Southampton, Taunton
2018-05-14
Active, closed
AstraZeneca
Phase 2
273
Aberdeen, Bristol, Cardiff, Durham, Edinburgh, Leicester, London, Manchester
2018-03-07
Active, closed
AstraZeneca
Phase 3
1,186
Leicester, London, Manchester
2017-06-01
Active, closed
AstraZeneca
Phase 1
117
Glasgow, London, Manchester, Southampton
2016-12-28
Active, closed
AstraZeneca
Phase 1/2
264
Cambridge, Dundee, Glasgow, Greater London, London, Manchester, Newcastle upon Tyne, Sutton
2016-03-17
Active, closed
AstraZeneca
Phase 3
953
Guildford, London, Manchester, Metropolitan Borough of Wirral, Nottingham, Taunton, Wolverhampton
2015-11-03
Active, closed
AstraZeneca
Phase 3
1,126
Cambridge, Cardiff, Glasgow, Leeds, London, Manchester, Metropolitan Borough of Wirral, Sheffield
2015-11-02
Active, closed
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
NCT02264678Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
DrugsSaruparib·Olaparib·Durvalumab·Carboplatin
AstraZeneca
Phase 1
358
Bristol, Cambridge, Coventry, London, Manchester, Oxford, Sutton, Withington
2014-10-31
Active, closed
AstraZeneca
Phase 3
510
Aberdeen, London, Manchester, Nottingham, Sutton, Wolverhampton
2013-09-25
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
DrugOlaparib
AstraZeneca
Phase 3
327
Birmingham, Cambridge, Coventry, Edinburgh, London, Manchester, Sutton
2013-09-03
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
DrugOlaparib
AstraZeneca
Phase 3
450
Birmingham, Cambridge, Coventry, Edinburgh, London, Sutton
2013-08-26
Active, closed
AstraZeneca
Phase 1
197
Edinburgh, London, Manchester, Newcastle upon Tyne, Northwood, Oxford, Sutton
2008-10-27
Active, closed
AstraZeneca
Phase 1
64
Dundee, Glasgow, London
2008-09-09
Rows per page Showing 1–139 of 139
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 7 November 2026. https://priyalifescience.com/clinical-trials-uk/city/london

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,878 studies in total at the last sync on 07 Nov 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 139 of those studies with a site in London that also match the filters currently applied.

How many clinical trials are recruiting in London?

65 of the 139 studies on this page are recruiting new participants as of the 07 Nov 2026, 03:15 UTC sync. A further 0 have not yet opened recruitment, 73 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (London), 139 studies
PhaseStudiesRecruitingShare
Phase 3833359.7%
Phase 2221115.8%
Phase 1/2171212.2%
Phase 11057.2%
Observational533.6%
Phase 4211.4%

Most active sponsors

Lead sponsors with the most studies (London)
Lead sponsorStudiesRecruiting
AstraZeneca13965
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.